Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Currently, the DNA damage response (DDR) pathway represents a key target for new cancer drug development. Advanced biliary tract cancer (BTC) has a poor prognosis because of the lack of efficacious treatment options. Although DNA repair pathway alterations have been reported in many patients with BTC, little is known regarding the effects of DDR-targeted agents against BTC. Materials and Methods In this study, nine BTC cell lines were exposed to the WEE1 inhibitor (AZD1775). In vitro, MTT assay, colony-forming assay, cell cycle analysis, phospho-histone H3 staining assay, Transwell migration assay, and western blot were performed. Then, to enhance the antitumor effect of AZD1775, the combination treatment of WEE1 inhibitor and ataxia telangiectasia mutated and Rad3 related (ATR) inhibitor (AZD6738) was conducted using MTT assay and comet assay. Finally, HuCCT-1 and SNU2670 xenograft models were established to confirm the anti-tumor effect of AZD1775 alone. Furthermore, the combination treatment was also evaluated in SNU2670 xenograft models. Results AZD1775 blocked the phosphorylation of CDC2 and CDC25C in all cell lines, but significantly increased apoptosis and S phase arrest in sensitive cells. However, increased p-ATR and phosphorylated ataxia telangiectasia mutated levels were observed in less sensitive cells. In addition, in vitro and in vivo data illustrated that AZD1775 combined with AZD6738 exerted more potent anti-tumor effects than either drug alone. Although WEE1 inhibition has promising anti-tumor effects in some BTC cells, the addition of ATR inhibitors could enhance its efficacy. Conclusion Taken together, this study supports further clinical development of DDR-targeted strategies as monotherapy or combination regimens for BTC.
Abstract
Purpose Currently, the DNA damage response (DDR) pathway represents a key target for new cancer drug development. Advanced biliary tract cancer (BTC) has a poor prognosis because of the lack of efficacious treatment options. Although DNA repair pathway alterations have been reported in many patients with BTC, little is known regarding the effects of DDR-targeted agents against BTC. Materials and Methods In this study, nine BTC cell lines were exposed to the WEE1 inhibitor (AZD1775). In vitro, MTT assay, colony-forming assay, cell cycle analysis, phospho-histone H3 staining assay, Transwell migration assay, and western blot were performed. Then, to enhance the antitumor effect of AZD1775, the combination treatment of WEE1 inhibitor and ataxia telangiectasia mutated and Rad3 related (ATR) inhibitor (AZD6738) was conducted using MTT assay and comet assay. Finally, HuCCT-1 and SNU2670 xenograft models were established to confirm the anti-tumor effect of AZD1775 alone. Furthermore, the combination treatment was also evaluated in SNU2670 xenograft models. Results AZD1775 blocked the phosphorylation of CDC2 and CDC25C in all cell lines, but significantly increased apoptosis and S phase arrest in sensitive cells. However, increased p-ATR and phosphorylated ataxia telangiectasia mutated levels were observed in less sensitive cells. In addition, in vitro and in vivo data illustrated that AZD1775 combined with AZD6738 exerted more potent anti-tumor effects than either drug alone. Although WEE1 inhibition has promising anti-tumor effects in some BTC cells, the addition of ATR inhibitors could enhance its efficacy. Conclusion Taken together, this study supports further clinical development of DDR-targeted strategies as monotherapy or combination regimens for BTC.
참고문헌 (25)
- Pilie PG, "State-of-the-art strategies for targeting the DNA damage response in cancer", Nat Rev Clin Oncol, 16, pp.81~104 (2019)
- Bogenberger JM, "Emerging role of precision medicine in biliary tract cancers", NPJ Precis Oncol, 2, pp.21~ (2018)
- 형재원, "Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin", Cancer Research and Treatment, 51(3), pp.901~909 (2019), 대한암학회
- Nakamura H, "Genomic spectra of biliary tract cancer", Nat Genet, 47, pp.1003~1010 (2015)
- Otto T, "Cell cycle proteins as promising targets in cancer therapy", Nat Rev Cancer, 17, pp.93~115 (2017)
- Matheson CJ, "Targeting WEE1 kinase in cancer", Trends Pharmacol Sci, 37, pp.872~881 (2016)
- Geenen JJ, "Molecular pathways : targeting the protein kinase Wee1 in cancer", Clin Cancer Res, 23, pp.4540~4544 (2017)
- Krajewska M, "Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination", Oncogene, 32, pp.3001~3008 (2013)
- Richer AL, "WEE1 kinase inhibitor AZD1775 has preclinical efficacy in LKB1-deficient non-small cell lung cancer", Cancer Res, 77, pp.4663~4672 (2017)
- Nam AR, "Therapeutic implication of HER2 in advanced biliary tract cancer", Oncotarget, 7, pp.58007~58021 (2016)
- 남아롱, "Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer", Cancer Research and Treatment, 51(3), pp.1167~1179 (2019), 대한암학회
- Oku Y, "Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP-E2F1-DNA damage response pathway axis", FEBS Open Bio, 8, pp.1001~1012 (2018)
- Wright G, "Dual targeting of WEE1 and PLK1 by AZD-1775 elicits single agent cellular anticancer activity", ACS Chem Biol, 12, pp.1883~1892 (2017)
- Jin MH, "ATM in DNA repair in cancer", Pharmacol Ther, 203, pp.107391~ (2019)
- Lecona E, "Targeting ATR in cancer", Nat Rev Cancer, 18, pp.586~595 (2018)
- Lin X, "Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint", J Exp Clin Cancer Res, 37, pp.129~ (2018)
- Jin J, "Combined inhibition of ATR and WEE1 as a novel therapeutic strategy in triple-negative breast cancer", Neoplasia, 20, pp.478~488 (2018)
- Chen D, "Wee1inhibitor AZD1775 combined with cisplatin potentiates anticancer activity against gastric cancer by increasing DNA damage and cell apoptosis", Biomed Res Int, 2018, pp.5813292~ (2018)
- Chen WT, "ATM regulation of IL-8 links oxidative stress to cancer cell migration and invasion", Elife, 4, pp.e07270~ (2015)
- Zheng H, "WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance", Sci Rep, 7, pp.43517~ (2017)
- Ahn DH, "Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance", Cancer, 122, pp.3657~3666 (2016)
- Sun L, "WEE1 kinase inhibition reverses G2", M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy, 2018, pp.7, e1488359~
- Sun LL, "Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing", Am J Cancer Res, 8, pp.1307~1316 (2018)
- Kim HJ, "Antitumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells", Int J Cancer, 140, pp.109~119 (2017)
- Toulany M, "Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair", Mol Cancer Res, 10, pp.945~957 (2012)